In 1980, she co-founded the Canadian Familial Polyposis Registry and served as Clinical Co-ordinator until her retirement in 2013.

She is Past-President of the Collaborative Group of the Americas on Inherited Colorectal Cancer and attended the first meeting of the Leeds Castle Polyposis group in 1985. She served on Council of LCPG (1999-2003) and InSiGHT (2003-2005).

Associate Professor,
Hvidovre University Hospital,Denmark.

Visiting Professor, the Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University. Graduated from Medical School of Tokyo Medical and Dental University in 1970.
Trained at Musashino Red Cross Hospital and Tokyo Medical and Dental University.
Member of Leeds Castle Polyposis Group and InSiGHT.
2005 – 2007, The 2nd chairman of InSiGHT: The scientific meeting was held in Yokohama in March 2007.

Professor and Chief of Colorectal Surgery at Helsinki University Hospital, retired 2014. He founded the Finnish Polyposis Registry in 1983 and undertook important research in the genetic background of Lynch syndrome, Peutz-Jeghers syndrome and juvenile polyposis.

He was present at the first meeting of the Leeds Castle Polyposis group in 1985 and was also a member of ICG-HNPCC and of InSiGHT.

Henry T Lynch MD, completed his MA in psychology at Denver University and was nearing completion of a PhD in human genetics at the University of Texas in Austin, when he entered medical school at the University of Texas Medical Branch in Galveston, from which he received his MD in 1960. He completed residency in internal medicine and medical oncology. He was on the faculty of the University of Texas MD Anderson Cancer Center in Houston before going to Creighton University School of Medicine in Omaha, Nebraska, in 1967, as Chairman of Preventive Medicine, advancing to full professor in 1972.

During the 1960’s, when cancer was considered an almost solely environmentally-caused disease, Dr Lynch demonstrated Mendelian inheritance patterns for what is now known as Lynch syndrome, and for the hereditary breast-ovarian cancer (HBOC) syndrome, which he subsequently helped link to the BRCA1 and BRCA2 genes. He provided early evidence for familial atypical multiple mole melanoma (FAMMM) and its association with pancreatic cancer when a CDKN2A mutation is present.